| Literature DB >> 27761168 |
Raoyrin Chanavirut1, Pattarapong Makarawate2, Ian A Macdonald3, Naruemon Leelayuwat4.
Abstract
BACKGROUND: Imbalances of the autonomic nervous (ANS), the cardiovascular system, and ionics might contribute to the manifestation of The Brugada Syndrome (BrS). Thus, this study has aimed to investigate the cardio-respiratory fitness and the responses of the ANS both at rest and during a sub-maximal exercise stress test, in BrS patients and in gender-matched and age-matched healthy sedentary controls.Entities:
Keywords: ANS, autonomic nervous system; BrS, total Brugada Syndrome; BrS-D, patients who took anti-arrhythmic drugs; BrS-ND, patients who did not take anti-arrhythmic drugs; Brugada Syndrome; CHO, carbohydrate.; ECG, electrocardiogram; Exercise; HF, high frequency; HR, heart rate; HRR, heart rate recovery; HRV, heart rate variability; Heart rate recovery; Heart rate variability; ICD, implantable cardioverter-defibrillator; K+, potassium; LF, low frequency; O2 peak, peak oxygen consumption; Potassium; RER, respiratory exchange ratio; RMSSD, the square root of the mean of the sum of the squares of differences between adjacent normal to normal intervals; SCD, sudden cardiac death; SDNN, standard deviation of all normal sinus RR intervals; VF, ventricular fibrillation; VT, ventricular tachycardia
Year: 2015 PMID: 27761168 PMCID: PMC5063266 DOI: 10.1016/j.joa.2015.09.001
Source DB: PubMed Journal: J Arrhythm ISSN: 1880-4276
Anthropometry and body composition of the subjects.
| Age (yr) | 47±8 | 50±6 |
| Height (m) | 1.66±0.04 | 1.69±0.04 |
| Body mass (kg) | 68.4±10.4 | 67.5±9.6 |
| BMI (kg/m2) | 24.7±3.64 | 23.6±2.48 |
| Lean body mass (kg) | 49.9±5.14 | 48.5±4.00 |
| Body fat (%) | 23±9 | 24±9 |
| Fat mass (kg) | 15.4±7.54 | 16.1±7.88 |
| Waist circumference (cm) | 78.0±9.70 | 78.3±7.30 |
| Hip circumference (cm) | 91.8±6.40 | 91.9±4.08 |
| WHR | 0.85±0.06 | 0.85±0.05 |
Data are expressed as mean±SD; n=23 control subjects, 11 Brugada Syndrome (BrS) patients without drug prescribe.
BMI=body mass index; WHR=waist to hip circumference ratio.
Blood chemistry parameters before and immediately after the exercise.
| Controls subjects | |||||
| Before | 4.94±0.49 | 139.5±2.85 | 4.50±0.50 | 102.0±2.39 | 29.0±2.41 |
| After | 4.96±0.39 | 139.3±2.24 | 4.37±0.34 | 102.2±2.20 | 27.5±2.87 |
| BrS patients | |||||
| Before | 4.85±0.36 | 138.4±2.01 | 5.15±0.79 | 102.1±2.17 | 28.7±3.67 |
| After | 4.82±0.50 | 138.6±2.06 | 4.91±0.71 | 102.1±1.97 | 28.3±2.67 |
Data are expressed as mean±SD; n=23 control subjects, 11 Brugada Syndrome (BrS) patients without drug prescribe.
Na+=sodium; K+=potassium; Cl−=chloride; =bicarbonate.
Significantly different from the control subjects (p<0.05).
Fig. 1Standard deviation of all normal to normal intervals (SDNN (ms)) at baseline, exercise and recovery period. Values are mean±SE; n=23 control subjects, 11 Brugada Syndrome (BrS) patients. αSignificantly different from baseline period within the group (p<0.05).
Fig. 3Low frequency component (LF(ms2)) at baseline, exercise, and recovery periods. Values are mean±SE; n=23 control subjects, 11 Brugada Syndrome (BrS) patients. αSignificantly different from baseline period within the group (p<0.05).
Fig. 2The square root of the mean of the sum of the squares of differences between adjacent normal to normal intervals (RMSSD (ms)) at the baseline, exercise, and recovery periods. Values are mean±SE; n=23 control subjects, 11 Brugada Syndrome (BrS) patients. αSignificantly different from baseline period within the group (p<0.05).
Fig. 4High frequency component (HF(ms2)) at baseline, exercise, and recovery periods. Values are mean±SE; n=23 control subjects, 11 Brugada Syndrome (BrS) patients. αSignificantly different from baseline period within the group (p<0.05).
Fig. 5Ratio of low to high frequency component (LF/HF ratio) at baseline, exercise, and recovery periods. Values are mean±SE; n=23 control subjects, 11 Brugada Syndrome (BrS) patients. α Significantly different from baseline period within the group (p<0.05). *Significantly different between groups at the same period (p<0.05).
Physiological characteristics before and responses to exercise.
| HRbefore (min−1) | 63±7 | 60±7 |
| HRpeak (min−1) | 118±17 | 101±14 |
| HRafter (min−1) | 76±10 | 69±9 |
| HRR (beats) | 28±8 | 22±8 |
| 22±7 | 16±4 | |
| Maximum exercise work load | ||
| W | 83±20 | 65±18 |
| W/kg | 1.24±0.34 | 0.95±0.26 |
| % | ||
| Low intensity-exercise | 41±8 | 44±6 |
| Moderate intensity-exercise | 61±6 | 59±7 |
| High intensity-exercise | 91±12 | 93±11 |
| RER | ||
| Low intensity-exercise | 0.78±0.07 | 0.80±0.07 |
| Moderate intensity-exercise | 0.82±0.07 | 0.84±0.07 |
| High intensity-exercise | 0.91±0.08 | 0.92±0.07 |
Data are expressed as mean±SD; n=23 control subjects, 11 Brugada Syndrome (BrS) patients without drug prescribe.
HR before the=heart rate before the exercise; %HRmax=percent of maximum heart rate; HRR=heart rate recovery (defined as decay of heart rate from peak exercise to one minute after the exercise termination); HRafter=heart rate immediately after the exercise during recovery period; =peak oxygen consumption.
Significantly different from the control subjects (p<0.05).
significantly different from high intensity-exercise (p<0.05).
significantly different from high intensity-exercise (p<0.1).
Fig. 6Responses of electrocardiogram before and termination of exercise and last minute of recovery period in a control subject and a Brugada Syndrome patient without drug prescribe. The standard calibration used was (25 mm/s and 10 mm/mV).
ST-segment amplitude after exercise termination for 1 and 5 min.
| Control subjects | 0.07±0.03 | 0.03±0.02 |
| BrS patients | 0.07±0.03 | 0.05±0.02 |
Data are expressed as mean±SD; n=23 control subjects, 11 Brugada Syndrome (BrS) patients without drug prescribe.